Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies

Elisa Pasqual, PhD; Sara Schönfeld, PhD; Lindsay M. Morton, PhD; Daphnée Villoing, PhD; Choonsik Lee, PhD; Amy Berrington de Gonzalez, DPhil; and Cari M. Kitahara, PhD, MHS

PURPOSE Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly. RAI has been associated with an increased risk of leukemia, but risks of second solid malignancies remain unclear. We aimed to quantify risks of second malignancies associated with RAI treatment for DTC in children and young adults, who are more susceptible than older adults to the late effects of radiation.

METHODS Using nine US SEER cancer registries (1975-2017), we estimated relative risks (RRs) for solid and hematologic malignancies associated with RAI (yes vs no or unknown) using Poisson regression among ≥5- and ≥2-year survivors of nonmetastatic DTC diagnosed before age 45 years, respectively.

RESULTS Among 27,050 ≥5-year survivors (median follow-up = 15 years), RAI treatment (45%) was associated with increased risk of solid malignancies (RR = 1.23; 95% CI, 1.11 to 1.37). Risks were increased for uterine cancer (RR = 1.55; 95% CI, 1.03 to 2.32) and nonsignificantly for cancers of the salivary gland (RR = 2.15; 95% CI, 0.91 to 5.08), stomach (RR = 1.61; 95% CI, 0.70 to 3.69), lung (RR = 1.42; 95% CI, 0.97 to 2.08), and female breast (RR = 1.18; 95% CI, 0.99 to 1.40). Risks of total solid and female breast cancer, the most common cancer type, were highest among ≥20-year DTC survivors (RRsolid = 1.47; 95% CI, 1.24 to 1.74; RRbreast = 1.46; 95% CI, 1.10 to 1.95). Among 32,171 ≥2-year survivors, RAI was associated with increased risk of hematologic malignancies (RR = 1.51; 95% CI, 1.08 to 2.01), including leukemia (RR = 1.92; 95% CI, 1.04 to 3.56). We estimated that 6% of solid and 14% of hematologic malignancies in pediatric and young adult DTC survivors may be attributable to RAI.

CONCLUSION In addition to leukemia, RAI treatment for childhood and young-adulthood DTC was associated with increased risks of several solid cancers, particularly more than 20 years after exposure, supporting the need for long-term surveillance of these patients.

J Clin Oncol 40:1439-1449. © 2022 by American Society of Clinical Oncology

INTRODUCTION The incidence of differentiated thyroid cancer (DTC) increased by an average of 3.6% per year between the mid-1970s and mid-2010s (from 4.56 to 14.42 per 100,000 person-years) in the United States. With 15,445 estimated new cases in 2020, thyroid cancer ranks as the second most common cancer in people younger than age 45 years in the United States. Use of radioactive iodine (RAI) for DTC treatment also increased through 2009, especially in young patients. However, in addition to providing limited to no survival benefit for localized DTC, RAI is associated with increased risks of short-term and long-term adverse outcomes, including secondary primary malignancies (SPMs), such as leukemia. In response to this evidence, the 2009 and 2015 American Thyroid Association guidelines committee issued recommendations against RAI therapy for low-risk DTCs < 1 cm and in support of lower levels of RAI administered activity for larger tumors. A similar approach was suggested in the pediatric guidelines, although without explicit discouragement of RAI treatment for low-risk DTCs, and the subject remains controversial. Children, adolescents, and young adults are particularly vulnerable to radiation-related secondary effects as a result of their increased tissue susceptibility and longer life expectancy. Of the few studies focused on risk of SPM after RAI for DTC in young patients, an increased risk for leukemia has been reported, specifically myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The results for solid malignancies have been less consistent, suggesting increased risks of salivary gland and kidney cancers, however, they were limited by short follow-up, small sample size, and lack of consideration of a minimal 5-year latency.
CONTEXT

Key Objective
We investigated whether radioactive iodine (RAI) therapy for childhood or young adulthood thyroid cancer is associated with increased risk of second primary malignancies. Although younger individuals are more susceptible to the carcinogenic effects of radiation, the few previous studies on young patients with thyroid cancer receiving RAI therapy have been small or included insufficient follow-up time for second malignancies.

Knowledge Generated
Among 2-year and 5-year survivors of pediatric or young-adulthood differentiated thyroid cancer identified from nine US cancer registries (1975-2017), RAI therapy was associated with 51% and 23% increased risks of total hematologic (including leukemia) and solid malignancies, respectively. Risks of total solid cancer and female breast cancer, the most common solid cancer type, were particularly elevated after more than 20 years of follow-up.

Relevance
These findings may help to guide treatment decision making in younger patients with thyroid cancer to ensure that the benefits of RAI therapy outweigh the risks.

METHODS

Cohort Definition
Individuals diagnosed with a first primary DTC (papillary or follicular carcinoma, Data Supplement, online only) before age 45 years between 1975 and 2017 were identified within nine SEER registries (San Francisco-Oakland, Connecticut, Detroit, Iowa, Hawaii, New Mexico, Seattle, Utah, and Atlanta), covering approximately 9% of the US population. Cases with distant metastasis at diagnosis (on the basis of Historic Stage A variable) were excluded. DTCs were further classified according to size and lymph node involvement, on the basis of the TNM definitions of the American Joint Committee on Cancer (AJCC), 7th and 8th editions. Age 45 years was used as the cutoff for young-adulthood DTC for consistency with AJCC staging definitions and previous studies. Sensitivity analyses restricted DTC cases to those diagnosed before age 40 years.

Follow-up for analyses of hematologic and solid malignancies started, respectively, 2 or 5 years after DTC diagnosis, accounting for the minimal latency period for radiation-induced carcinogenesis. This exclusion also reduced the potential for surveillance bias, as the likelihood of incidental cancer detection is highest immediately following DTC diagnosis. Follow-up ended at SPM diagnosis, death, last period between radiation exposure and solid malignancy development.

Here, we aimed to estimate risk of SPM associated with RAI treatment for DTC in childhood and young adulthood (age < 45 years) using the US SEER cancer registry database (1975-2017). In addition to confirming the more well-established association of RAI treatment and leukemia risk, the inclusion of nearly 10 more years of follow-up compared with earlier SEER-based studies on this topic allowed for more precise assessment of solid malignancy risks.

Exposure and Outcome Definition
In SEER, radiation given as part of the first course of therapy is classified as yes or “no or unknown,” with “no or unknown” defined as the absence of evidence of radiation therapy during medical record review. RAI therapy was defined as receipt of radioisotope therapy after 1988 or “other radiation” (n = 1,116) or “radiation NOS” (n = 20), as opposed to external beam radiotherapy, before 1988. Patients whose radiation treatment was recorded as beam radiation before 1988 or “other radiation” or “radiation NOS” (n = 898) after 1988 were excluded.

The classification of hematologic malignancies evolved over time. Before 2001, MDS and myeloproliferative neoplasms (MPN) were not captured in SEER. To evaluate the impact of these changes, we performed a secondary analysis of myeloid malignancies, including MDS and MPN (Data Supplement), using SEER-18 (2000-2017), which covers a shorter timeframe but larger US population proportion (28%).

Statistical Methods
Using SEER-9 (or SEER-18) data, we obtained the observed and expected number of each SPM site. Expected numbers were derived from SEER cancer incidence rates, stratified on age (5-year groups), calendar period (5-year groups), sex, and race (White, Black, other). We conducted both an internal and an external risk comparison.
Second Primary Malignancy After Use of Radioactive Iodine

Internal comparisons (primary analysis). Among patients with DTC, we estimated relative risks (RRs) and 95% CIs of SPMs according to receipt of RAI (yes v no or unknown) using multivariable Poisson regression models that were adjusted through stratification for sex, age at DTC diagnosis, and latency (time between DTC and SPM diagnoses) and were indirectly adjusted for attained age and calendar year using the log of the expected number of cases as an offset.\(^42\) RRs for solid and breast cancers (the most common SPM in this population) were also stratified by race, sex, age at exposure, follow-up, year of diagnosis, and DTC stage. Tests for heterogeneity were conducted using likelihood ratio tests.

Using parameters from the Poisson regression models, we estimated excess numbers of solid, breast, and hematologic malignancies attributable to RAI exposure. By dividing this number by the total number of second primary malignancies in \(\geq 1\)-year survivors, we obtained a conservative estimate of the proportion of second cancers in all DTC survivors attributable to RAI (attributable risk), assuming no excess solid or hematologic malignancies were attributed to radiation in the first 5 and 2 year after exposure, respectively.

External comparisons (secondary analysis). For consistency with earlier SEER-based studies,\(^6,7\) we computed standardized incidence ratios (SIRs) and 95% CIs for RAI-treated and non–RAI-treated patients. SIRs are the observed divided by expected number of cancers. Confounding was of particular concern with external comparisons, owing to the differences between patients with DTC and the general population (eg, health care access, socioeconomic status, lifestyle characteristics, and smoking status).\(^43-46\) To evaluate confounding by smoking, we compared SIRs for smoking-related versus non–smoking-related cancers.\(^47\) We also estimated the standardized mortality ratio (SMR) for chronic obstructive pulmonary disease (COPD), a smoking-related but not radiation-related outcome.\(^48\)

Cumulative incidence. We estimated cumulative incidence of second solid and hematologic malignancies by time since DTC diagnosis, accounting for competing risk of death and other cancers, that is, hematologic malignancies were treated as competing risk for solid malignancies and vice versa.

Analyses were conducted using SEER*Stat (version 8.3.8), the AMFIT module of Epicure (version 2.00.02), and STATA (stcompet function).\(^49\)

Ethical Approval

Ethical approval was not required for the use of anonymized publicly available data.\(^50\)

RESULTS

We identified 36,311 pediatric and young adults diagnosed with nonmetastatic DTC (accounting for 97% of all DTCs) during 1975-2017. Of these, 81% were female and 45% were treated with RAI (Table 1). RAI use was higher among males (50%) than females (44%), highest among patients younger than age 15 years (55%), and lowest in Black patients (40%). Overall, RAI use increased markedly from 9% to 55% during 1975-2009 and subsequently declined to 39% in 2017 (Fig 1). Similar trends were observed by DTC size. Maximum follow-up was 43 years.

Second Solid Malignancies

Among the 36,311 identified patients, 27,050 were \(\geq 5\)-year survivors (Data Supplement), and 1,524 second solid malignancies were observed over follow-up (median = 15.6 years). RAI therapy was associated with an increased risk of solid malignancies (RR = 1.23; 95% CI, 1.11 to 1.37; Fig 2). The cumulative incidence of second solid malignancy at 20 years after DTC diagnosis was 5.6% (95% CI, 5.0 to 6.0) for RAI-treated patients and 5.0% (95% CI, 4.6 to 5.4) for those not treated with RAI, and this difference increased with subsequent follow-up (12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3). Among the highly radiation-exposed organs, RAI-associated risk was elevated for cancers of the salivary gland (RR = 12.5% [11.3 to 13.8] and 10.2% [9.5 to 11.0], respectively, at 30 years; Fig 3).
non–RAI-treated patients were elevated. The SMR for COPD was reduced in both RAI-treated (0.46; 95% CI, 0.21 to 0.88) and non–RAI-treated (0.50; 95% CI, 0.34 to 0.72) patients.

The results were similar for patients diagnosed before age 40 years (Data Supplement), with stronger RRs for lung (RR = 1.71; 95% CI, 1.04 to 2.84) and uterine (RR = 1.98; 95% CI, 1.20 to 3.28) cancer.

**Second Hematologic Malignancies**

Of the 32,171 2-year survivors (Data Supplement), 146 were diagnosed with second hematologic malignancies over follow-up (median = 13 years). RAI therapy was associated with an increased risk of leukemia (RR = 1.92; 95% CI, 1.04 to 3.56), specifically nonlymphocytic leukemia (RR = 2.17; 95% CI, 1.03 to 4.55; Fig 2). No increased risk was found for Hodgkin or non-Hodgkin lymphoma. We estimated that 22 (95% CI, 4 to 41) excess hematologic malignancies were attributable to RAI in this cohort, corresponding to an attributable risk of 14% (3 to 26). The cumulative incidence of second hematologic malignancy at 5 years after DTC diagnosis was 0.10% (95% CI, 0.06 to 0.17) for RAI-treated patients and 0.05% (0.03

---

**TABLE 1. Characteristics of Differentiated Thyroid Cancer Patients Age < 45 Years in SEER 9 (1975-2017) Database**

| Characteristics                              | RAI, No. (%) | No or Unknown RAI, No. (%) |
|----------------------------------------------|--------------|----------------------------|
| Total                                        | 16,296 (45)  | 20,015 (55)                |
| Sex                                          |              |                            |
| Male                                         | 3,361 (50)   | 3,339 (50)                 |
| Female                                       | 12,935 (44)  | 16,676 (56)                |
| Age at diagnosis, years                      |              |                            |
| 0 to < 15                                    | 201 (55)     | 167 (45)                   |
| 15 to < 25                                   | 2,261 (47)   | 2,569 (53)                 |
| 25 to < 45                                   | 9,869 (44)   | 12,321 (56)                |
| Race or ethnicity                            |              |                            |
| White                                        | 13,066 (45)  | 16,273 (55)                |
| Black                                        | 812 (40)     | 1,221 (60)                 |
| Other                                        | 2,269 (51)   | 2,165 (49)                 |
| Missing                                      | 149 (30)     | 356 (70)                   |
| Attained age at event (any SPM), median (25th, 75th percentile) | 43 (20; 50) | 45 (16.5; 53) |
| Follow-up time (years), median (25th; 75th percentile) | 10.2 (4.9; 17.7) | 12.7 (4.8; 24.5) |
| Year of treatment                            |              |                            |
| 1975-2000                                    | 4,934 (35)   | 8,986 (65)                 |
| 2000-2017                                    | 11,362 (51)  | 11,029 (49)                |
| Tumor histology                              |              |                            |
| Papillary                                    | 14,907 (45)  | 18,266 (55)                |
| Follicular                                    | 1,389 (44)   | 1,749 (56)                 |
| Thyroid cancer stage on the basis of TNM     |              |                            |
| Size < 4 cm and no lymph node involvement    | 4,160 (36)   | 7,407 (64)                 |
| Size ≥ 4 cm or lymph node involvement        | 9,487 (62)   | 5,932 (38)                 |
| Unknown                                      | 2,649 (28)   | 6,676 (72)                 |

Abbreviations: RAI, radioactive iodine; SPM, secondary primary malignancy.

*Before exclusions on the basis of minimum latency period. The characteristics of the cohort after exclusion of 5- and 2-year latency period are reported in the Data Supplement.

*Unless otherwise specified.
to 0.10) for those not treated with RAI. At 20 years, it was 0.67% (0.49 to 0.88) and 0.37% (0.27 to 0.50), respectively (Fig 3).

**SEER-18 (2000-2017) database.** Of the 51,902 2-year survivors (Data Supplement), 46 second myeloid malignancies were observed over follow-up, of which 22 were MDS or AML and 24 MPN or MDS/MPN (Data Supplement). RRs were nonsignificantly increased for both MDS or AML (RR = 2.78; 95% CI, 0.90 to 8.62) and for MPN or MDS/MPN (RR = 2.77; 95% CI, 0.89 to 8.59).

**DISCUSSION**

RAI is commonly used for DTC treatment, particularly in young patients.9 However, children and young adults are particularly susceptible to radiation-induced carcinogenesis, and they have a longer life span to develop radiation-related SPMs.28 In this US population–based study of survivors of pediatric and young-adult DTC, use of RAI was associated with increased risk of solid malignancies, especially after > 20 years of follow-up. This risk increased with exposure at younger ages. These findings may explain the lack of evidence of increased risk of solid malignancies in previous studies relying on shorter follow-up or focused primarily on older patients.15,51

Salivary gland, stomach, urinary bladder, and kidney are estimated to be highly exposed from RAI therapy for DTC (absorbed doses > 1 Gy for 100 mCi administered activity; Data Supplement) owing to the ability of these and other nearby organs and tissues to concentrate RAI.38,52,53 RAI therapy was associated with a two-fold risk of cancer of the salivary gland, which is highly radiosensitive,54 consistent with previous studies.6,7,17,20 Although stomach and urinary bladder are also radiosensitive,54,55 the kidney appears to be less so.55 Risks for stomach and kidney cancer were not significantly elevated, similar to previous reports.17,18,20,30,56,57 Based on very few cases, risk for urinary bladder cancer was not elevated. The female breast, uterus, lung, and bone marrow are also radiosensitive,31 and absorbed doses from RAI therapy for DTC are estimated to be between 0.1 and 0.5 Gy for 100 mCi administered activity. In our cohort, breast cancer was the most common SPM. RAI-associated risk for breast cancer was increased most markedly after 20 years of follow-up. The stronger relative risk associated with younger age at exposure is consistent with studies of other radiation-exposed populations.32,58

The positive findings for lung and uterine cancer, somewhat stronger in the sensitivity analysis restricted to DTC diagnosed before age 40 years, were consistent with previous studies.17,19,59 Studies of other radiation-exposed populations, including the Life-Span Study of Japanese atomic bomb survivors, showed a statistically significant dose-response between radiation exposure and both lung and uterine cancer, the latter being more pronounced for women exposed during puberty; however, our study included too few cases among very young patients with DTC to evaluate this.60,61
Our results confirmed the increased risk of hematologic malignancies following RAI treatment. It is well established that leukemia, especially AML and CML, are radiation-induced and that risk is higher for children than adults for the same unit radiation dose. No association was observed for lymphoid malignancies, which are not clearly radiation-associated. Statistical power was insufficient to evaluate associations for lymphoma subtypes, which are etiologically heterogeneous.

Both the cumulative incidence curves and RRs stratified by follow-up were consistent in showing different exposure latency periods for hematologic and solid malignancies, with shorter-term elevated risks for hematologic malignancies and longer-term elevated risks (increasing over time) for solid malignancies. These findings are in agreement with those from other radiation-exposed populations, including the long-standing Japanese atomic bomb survivor cohorts.

Importantly, limitations of the SEER registries include underascertainment of radiation therapy and lack of detailed treatment data. SEER captures information on first course of therapy; so, any treatment received during a recurrence is not captured. Radiotherapy (including RAI) may be underascertained if not recorded in medical records reviewed by SEER; this is more likely for radiotherapy administered in outpatient settings. Underascertainment of RAI would likely bias RR estimates toward the null. As SEER does not collect information on RAI administered activity or patient-specific organ doses. We observed higher RRs in patients treated before 2000, potentially reflecting both longer follow-up and higher administered activity. According to previous studies, higher RAI administered activity is associated with greater risk of SPMs, with risks most evident over 100 mCi. To our knowledge, no previous studies of patients with DTC have evaluated these risks in relation to organ dose, the gold standard exposure measure in radiation epidemiology studies. In a recent study of patients treated for hyperthyroidism, higher organ doses were positively associated with total solid cancer.

### Table: Second Primary Malignancy Site

| Second Primary Malignancy Site | Grouping | No. of Cases: RAI Versus No or Unknown RAI | RR (95% CI) |
|--------------------------------|----------|------------------------------------------|-------------|
| All solid cancer (b) | Dose > 1,000 mGy (a) | 561/983 | 1.23 (1.11 to 1.37) |
| Kidney | 34/51 | 1.34 (0.88 to 2.09) |
| Salivary gland (c) | 12/10 | 2.15 (0.91 to 5.08) |
| Stomach (c) | 16/14 | 1.61 (0.70 to 3.69) |
| Urinary bladder (c) | 5/14 | 0.78 (0.28 to 2.18) |
| Colon and rectum (c) | Dose 500-999 mGy (a) | 43/66 | 1.28 (0.88 to 1.89) |
| Breast cancer (c, d) | 214/377 | 1.18 (0.59 to 1.40) |
| Melanoma of the skin | 46/62 | 1.36 (0.92 to 2.01) |
| Lung and bronchus (c) | 42/78 | 1.42 (0.97 to 2.03) |
| Cor pulmonale (d) | 42/57 | 1.55 (1.03 to 2.32) |
| Prostate (c,d) | 39/70 | 1.36 (0.91 to 2.04) |
| Ovary (c,d) | 11/20 | 1.17 (0.55 to 2.47) |
| Pancreas (c) | 11/18 | 1.52 (0.70 to 3.27) |
| Brain (c) | 9/14 | 1.36 (0.58 to 3.19) |
| Cervix uteri (d) | 7/12 | 0.96 (0.38 to 2.51) |
| Soft tissue and heart (c) | 5/11 | 0.88 (0.30 to 2.61) |
| Liver (c) | < 3/8 | 0.26 (0.03 to 2.06) |

### Table: Hematologic malignancies

| Hematologic malignancies | Grouping | No. of Cases: RAI Versus No or Unknown RAI | RR (95% CI) |
|--------------------------|----------|------------------------------------------|-------------|
| All lymphatic and hematopoietic | Bone marrow dose > 100-499 mGy (a) | 65/81 | 1.51 (1.08 to 2.11) |
| Non-Hodgkin lymphoma | 32/50 | 1.27 (0.81 to 2.00) |
| Myeloma | 6/5 | 2.36 (0.70 to 7.94) |
| Hodgkin lymphoma | 5/5 | 1.36 (0.30 to 4.83) |
| Leukemia (c) | 22/21 | 1.92 (1.04 to 3.56) |
| Lymphocytic leukemia (c) | 5/8 | 1.45 (0.46 to 4.60) |
| Nonlymphocytic leukemia (c) | 17/13 | 2.17 (1.03 to 4.55) |
| Acute nonlymphocytic leukemia (c) | 8/8 | 2.27 (0.79 to 6.51) |
| Chronic nonlymphocytic leukemia | 8/8 | 2.39 (0.80 to 7.14) |

**FIG 2.** RR and 95% CI for solid and hematologic malignancies, adjusted for age at DTC diagnosis, sex, and latency. (a) Dose groups were defined according to the reported absorbed dose per administered activity in ICRP Publication 128, on the basis of an administered activity of 100 mCi in a 15-year-old patient. See the Data Supplement for details. Within each dose group, solid cancer sites are ordered according to the number of events observed in RAI-treated patients. (b) The category all solid cancer includes, in addition to the ones listed in this table, those cancer sites with < 10 events total (see the Data Supplement for details). (c) Radiosensitive organs. Those are organs for which a dose-response relationship has been described in the Japanese atomic bomb survivors’ study. (d) Prostate risk analysis was restricted to men only, whereas ovary, breast, and corpus and cervical uterus cancer analyses were restricted to women. DTC, differentiated thyroid cancer; ICRP, International Commission on Radiological Protection; RAI, radioactive iodine; RR, relative risk.
and female breast cancer mortality and nonsignificant positive associations were observed for other solid cancer outcomes, including uterine cancer mortality.\textsuperscript{71} Although DTC therapy uses higher administered activities compared with hyperthyroidism therapy, this does not necessarily translate into higher organ doses. Correlations between administered activity and organ-specific doses depend partly on the volume of remaining thyroid tissue and its

![Graph A](image1.png)

**FIG 3.** Cumulative incidence of second primary (A) solid and (B) hematologic malignancies among differentiated thyroid cancer survivors, stratified by RAI use (yes \(v\) none or unknown). \textsuperscript{a}Data were cut at 40 years (35 for hematologic malignancies) of follow-up since DTC diagnosis, because of small size of risk set after 40 years. DTC, differentiated thyroid cancer; RAI, radioactive iodine.

| Characteristics                        | No. of Cases: RAI Versus No or Unknown RAI | RR (95% CI)         | \(P\) of Interaction |
|----------------------------------------|-------------------------------------------|---------------------|----------------------|
| Sex                                    |                                           |                     |                      |
| Male                                   | 126/200                                   | 1.35 (1.08 to 1.70) |                      |
| Female                                 | 435/763                                   | 1.20 (1.07 to 1.40) | .33                  |
| Race                                   |                                           |                     |                      |
| White                                  | 440/82                                    | 1.16 (1.03 to 1.31) |                      |
| Black                                  | 25/49                                     | 1.36 (0.83 to 2.24) |                      |
| Other                                  | 96/92                                     | 1.43 (1.07 to 1.91) | .46                  |
| Age at RAI administration, years       |                                           |                     |                      |
| 0 to < 25                              | 41/60                                     | 1.60 (1.07 to 2.40) |                      |
| 25 to < 35                             | 175/312                                   | 1.31 (1.08 to 1.58) |                      |
| 35 to < 45                             | 345/591                                   | 1.16 (1.02 to 1.33) | .07                  |
| Follow-up time, years                  |                                           |                     |                      |
| 5 to < 10                              | 142/184                                   | 1.01 (0.81 to 1.25) |                      |
| 10-20                                  | 232/336                                   | 1.19 (1.00 to 1.40) |                      |
| > 20 years                             | 187/443                                   | 1.47 (1.24 to 1.74) | .007                 |
| Year at RAI administration              |                                           |                     |                      |
| Before 2000                            | 420/824                                   | 1.31 (1.17 to 1.48) |                      |
| After 2000                             | 141/139                                   | 0.94 (0.74 to 1.19) | .01                  |
| Thyroid cancer stage on the basis of TNM |                                           |                     |                      |
| Size < 4 cm AND no lymph node involvement | 183/242                                   | 1.11 (0.92 to 1.35) |                      |
| Size ≥ 4 cm OR lymph node involvement   | 230/212                                   | 1.28 (1.06 to 1.55) | .27                  |

**FIG 4.** RRs and 95% CI for second solid malignancies stratified by patient and differentiated thyroid cancer characteristics. RAI, radioactive iodine; RR, relative risk.
uptake of radioiodine. Finally, underascertainment of SPM because of migration outside the SEER catchment areas may have reduced the precision of RRs but was not expected to have biased these estimates.

Despite these limitations, SEER registries are population-based, avoiding potential selection biases that could arise from hospital-based studies. The large size of the cohort, long duration of follow-up, and focus on internal cohort comparisons were also key strengths of this investigation compared with previous studies, especially those focused on childhood and/or young adulthood DTC survivors. We found that the risks of second solid cancers, including breast cancer, increased with time since diagnosis. This finding is consistent with known latency periods between radiation exposure and solid cancer occurrence, and is unlikely to be explained by medical surveillance. External comparisons (SIR estimates), which were the focus of most previous SEER-based studies on this topic, are prone to confounding by cancer risk factors that differ between DTC survivors and the general population (socioeconomic status, access to health care and cancer screenings, smoking, and body mass index [BMI]). Confounding by smoking seemed to have biased the SIRs for smoking-related cancers (eg, lung, colon, ovarian, and cervical) and the SMR for COPD in the negative direction, while confounding by BMI may have biased the SIRs for obesity-related cancers (eg, corpus uteri, kidney, colon, and postmenopausal breast) in the positive direction. Since RAI therapy was not randomly assigned in this observational study, confounding of the internal comparisons (RRs) by cancer risk factors that differ for those receiving versus not receiving RAI therapy was possible. However, confounding by smoking history and BMI was unlikely as these are not factors influencing SPM risk. Long-term surveillance for SPMs is unlikely to differ by receipt of RAI therapy, as supported by a recent study that reported no difference in level of worry about SPMs for patients treated with or without RAI.

We estimated that 6%, 5%, and 14% of second solid, breast, and hematologic malignancies, respectively, occurring in ≥ 1-year DTC survivors may be attributable to RAI. This is likely a conservative estimate, as the current study was not designed to estimate lifetime risks. The modest RRs together with the relative rarity of SPMs in DTC survivors means that the absolute lifetime excess risks associated with RAI are likely to be small.

FIG 5. RRs and 95% CI for second female breast cancer stratified by patient and differentiated thyroid cancer characteristics. No information was available to identify premenopausal and postmenopausal breast cancer; however, 60% of breast cancer cases were diagnosed after 51 years of age, the average menopausal age in US women. RAI, radioactive iodine; RR, relative risk.
after exposure, our study of pediatric and young adult patients with DTC indicates that, in the longer term, RAI increases the risk of several types of solid cancer, including breast cancer. Continued discussion and evaluation of RAI therapy in the management in DTC in pediatric and young adult patients is warranted to ensure that the benefits outweigh the risks.

**AFFILIATIONS**

1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
2. Institut de Cancérologie de l'Ouest, Saint-Herblain, France

**CORRESPONDING AUTHOR**

Cari M. Kitahara, PhD, MHS, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr, Rm. 7E-456, Bethesda, MD 20892; e-mail: kitaharac@mail.nih.gov.

**SUPPORT**

Supported by the Intramural Research Program of the National Cancer Institute.

**REFERENCES**

1. Lim H, Devesa SS, Sosa JA, et al: Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 317:1338-1348, 2017
2. Bernier M-O, Withrow DR, Berrington de Gonzalez A, et al: Trends in pediatric thyroid cancer incidence in the United States, 1998-2013. Cancer 125: 2497-2505, 2019
3. Ferlay J, Ervik M, Colombet M, et al: Global Cancer Observatory: Cancer Today. Lyon, France, International Agency for Research on Cancer, 2020
4. Klein Hesselink MS, Nies M, Bocca G, et al: Pediatric differentiated thyroid carcinoma in The Netherlands: A nationwide follow-up study. J Clin Endocrinol Metab 101:2031-2039, 2016
5. Goldfarb M, Sener SF: Comparison of radioiodine utilization in adolescent and young adult and older thyroid cancer patients. Endocr Pract 20:405-411, 2014
6. Iyer NG, Morris L.G.T., Tuttle RM, et al: Rising incidence of second cancers in patients with low-risk (TNM) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4349-4446, 2011
7. Marti JL, Jain KS, Morris L.G.T.: Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid 25:681-687, 2015
8. Pole JD, Zuk AM, Wasserman JD: Diagnostic and treatment patterns among children, adolescents, and young adults with thyroid cancer in Ontario: 1992-2010. Thyroid 27:1025-1033, 2017
9. Haymart M, Banerjee M, Stewart A, et al: Use of radioactive iodine for thyroid cancer. JAMA 306:721-728, 2011
10. Hay JD, Gonzalez-Losada T, Reilandt MS, et al: Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34:1192-1202, 2010
11. Jonklaas J, Cooper DS, Ain KB, et al: Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20:1423-1424, 2010
12. McDougall IR, Hay JD: ATA guidelines: Do patients with stage I thyroid cancer benefit from (131)I?. Thyroid 17:595-596, 2007; author reply 596-597
13. James DL, Ryan EJ, Davey MG, et al: Radioiodine remnant ablation for differentiated thyroid cancer: A systematic review and meta-analysis. JAMA Otolaryngol Head Surg 147:544-552, 2011
14. Clément SC, Peeters RP, Ronckers CM, et al: Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma—A systematic review. Cancer Treat Rev 41:925-934, 2015
15. Yu CY, Saeed O, Goldberg AS, et al: A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. Thyroid 28:1662-1673, 2018
16. Khang AR, Cho SW, Choi HS, et al: The risk of secondary primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf) 83:117-123, 2015
17. Rubino C, de Vathaire F, Dottorini ME, et al: Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644, 2003
18. Seo GH, Ae Kong K, Kim BS, et al: Radioactive iodine treatment for children and young adults with thyroid cancer in South Korea: A population-based study. J Clin Endocrinol Metab 106:e2580-e2588, 2021
19. Teng C-J, Hu Y-W, Chen S-C, et al: Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: A nationwide population-based study. J Natl Cancer Inst 108:djv014, 2016
20. Endo M, Liu JB, Dougan M, et al: Incidence of secondary malignancy in patients with papillary thyroid cancer from Surveillance, Epidemiology, and End Results 13 dataset. J Thyroid Res 2018:8765369, 2018
21. Molenaar RJ, Sijtsema S, Radivojevitch T, et al: Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol 36:1831-1839, 2018
22. Teepen JC, Curtis RE, Dorees GM, et al: Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. Leukemia 32:2580-2589, 2018
23. Cooper DS, Doherty GM, Haugen BR, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214, 2009
24. Haugen BR, Alexander EK, Bible KC, et al: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1-133, 2016

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.21.01841.

**AUTHOR CONTRIBUTIONS**

Conception and design: Elisa Pasqual, Lindsay M. Morton, Daphnée Villoing, Amy Berrington de Gonzalez, Cari M. Kitahara
Financial support: Cari M. Kitahara
Collection and assembly of data: Cari M. Kitahara
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

**Journal of Clinical Oncology** 1447
25. Francis GL, Waguespack SG, Bauer AJ, et al: Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25:716-759, 2015
26. Parisi MT, Elsayem A, Mankoff D: Management of differentiated thyroid cancer in children: Focus on the American Thyroid Association pediatric guidelines. Semin Nucl Med 46:147-164, 2016
27. Parisi MT, Khalatbari H, Parikh SR, et al: Initial treatment of pediatric differentiated thyroid cancer: A review of the current risk-adaptive approach. Pediatr Radiol 49:1391-1403, 2019
28. UNSCEAR: Sources, Effects and Risks of Ionizing Radiation, Volume II: Scientific Annex B—Effects of Radiation Exposure of Children. New York, NY, United Nations, 2013
29. Albano D, Bertagna F, Panarotto MB, et al: Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. Pediatr Blood Cancer 64:e26595, 2017
30. Adly MH, Sobhy M, Rezk MA, et al: Risk of second malignancies among survivors of pediatric thyroid cancer. Int J Clin Oncol 23:625-633, 2018
31. National Research Council: Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington DC, The National Acadamy Press, 2006
32. Berrington de Gonzalez A, Bouville A, Rajaraman P, et al: Chapter 13: Ionizing Radiation. Cancer Epidemiology & Prevention. New York, NY, Oxford University Press,[Internet]
33. SEER 9: Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence—SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017)—Linked to County Attributes—Time Dependent (1990-2017) Income/Rurality, 1969-1977 Counties, National Cancer Institute, DCPPS, Surveillance Research Program, Released April 2020, Based on the November 2019 Submission. Surveillance Epidemiol End Results SEER Program, 2019. www.seercancer.gov
34. Edge S, Byrd D, Compton C, et al: AJCC Cancer Staging Manual (ed 7), Paris, France, Springer, 2010
35. Tuttte RM, Haugen B, Perrier ND: Updated American Joint Committee on Cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): What changed and why? Thyroid 27:751-756, 2017
36. Adolescent and Young Adult Oncology Review Group: Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults With Cancer. US Department of Health and Human Services, 2006. https://www.livestrong.org/content/closing-gap-research-and-care-imperatives-adolescents-and-young-adults-cancer
37. Curtis RE, Freedman D, Ron E, et al: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Cancer Institute, 2006
38. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. Amsterdam, the Netherlands, Elsevier, 2015
39. Bojda P, Krejčí D, Bubníková-Bučková M, et al: Exposure to low-dose, high-energy photon radiation. J Natl Cancer Inst Monogr 2020:133-153, 2020
39. Arber DA, Orazi A, Hasserjian R, et al: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127: 2391-2405, 2016
40. Craig BM, Rollison DE, List AF, et al: Underreporting of myeloid malignancies by United States Cancer Registries. Cancer Epidemiol Biomarkers Prev 21: 474-481, 2012
41. SEER 18: SEER*Stat Database: Incidence - SEER 18 Regs Excluding AK Custom Data (With Additional Treatment Fields), Nov 2018 Sub (2000-2016) < Katrina/Rita Population Adjustment-> Linked to County Attributes - Time Dependent, 1969-2017 Counties, National Cancer Institute, DCPPS, Surveillance Research Program, Released April 2019, Based on the November 2018 Submission. Surveillance Epidemiol End Results SEER Program, 2019
42. Yasui Y, Liu Y, Neglia JP, et al: A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol 158:1108-1113, 2003
43. Cho YA, Kim J: Thyroid cancer risk and smoking status: A meta-analysis. Cancer Causes Control 25:1187-1195, 2014
44. Morris LGT, Sikora AG, Tosteson TD, et al: The increasing incidence of thyroid cancer: The influence of access to care. Thyroid 23:885-891, 2013
45. Yoon J, Park B: Factors associated with health behaviors in thyroid cancer survivors. J Cancer Prev 25:173-180, 2020
46. Kitahara CM, Linet MS, Beane Freeman LE, et al: Cigarette smoking, alcohol intake, and thyroid cancer risk: A pooled analysis of five prospective studies in the United States. Cancer Causes Control 23:1615-1624, 2012
47. IARC: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100 E, Personal Habits and Indoor Combustions. Lyon, France, IARC, 2012
48. Schubauer-Bergan MK, Kirschene de Gonzalez A, Cardis E, et al: Evaluation of confounding and selection bias in epidemiological studies of populations exposed to low-dose, high-energy photon radiation. J Natl Cancer Inst Monogr 2020:133-153, 2020
49. Presto DL, Lubin JH, Pierce DA, et al: Epicure Risk Regression and Person-Year Computation Software: Command Summary and User Guide. Ottawa, Canada, Risk Sciences International, 2015
50. SEER: Surveillance, Epidemiology, and End Results Program. SEER. https://seercancer.gov/index.html
51. Mei X, Yao X, Feng F, et al: Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients. BMC Cancer 21:543, 2021
52. Kolbert KS, Pentlow KS, Pearson JR, et al: Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med 48:143-149, 2007
53. Guiu-Souto J, Sánchez Garcia M, et al: Adaptive biokinetic modelling of iodine-131 in thyroid cancer treatments: Implications on individualised internal dosimetry. J Radiol Prot 36:1501-1511, 2016
54. Sakata R, Preston DL, Brenner AV, et al: Radiation-related risk of cancers of the upper digestive tract among Japanese atomic bomb survivors. Radiat Res 192: 331-344, 2019
55. Grant EJ, Yamamura M, Brenner AV, et al: Radiation risks for the incidence of kidney, bladder and other urinary tract cancers: 1958-2009. Radiat Res 195: 140-148, 2020
56. Kim C, Shi X, Pan D, et al: The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid 23:575-582, 2013
57. Berthe E, Henry-Amia L, Michels J-J, et al: Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31:685-691, 2004
58. Lin C-Y, Lin C-L, Huang W-S, et al: Risk of breast cancer in patients with thyroid cancer receiving or not receiving 131I treatment: A nationwide population-based cohort study. J Nucl Med 57:685-690, 2016
59. Ko K-Y, Yao X, Feng F, et al: Risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: A nationwide population-based cohort study. Eur J Nucl Med Mol Imaging 42:1172-1178, 2015
Second Primary Malignancy After Use of Radioactive Iodine

60. Cahoon EK, Preston DL, Pierce DA, et al: Lung, laryngeal and other respiratory cancer incidence among Japanese atomic bomb survivors: An updated analysis from 1958 through 2009. Radiat Res 187:538-548, 2017
61. Utada M, Brenner AV, Preston DL, et al: Radiation risks of uterine cancer in atomic bomb survivors: 1958-2009. JNCI Cancer Spectr 2:pky081, 2018
62. Molenaar RJ, Pleyer C, Radivoyevitch T, et al: Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia 32:952-959, 2018
63. Little MP, Wakeford R, Borrego D, et al: Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: A pooled analysis of nine historical cohort studies. Lancet Haematol 5:e346-e398, 2018
64. Hsu W-L, Preston DL, Soda M, et al: The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res 179:361-382, 2013
65. Harbron RW, Pasqual E: Ionising radiation as a risk factor for lymphoma: A review. J Radiol Prot 40:R151-R158, 2020
66. Morton LM, Slager SL, Cerhan JR, et al: Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Nati Cancer Inst Monogr 2014:130-144, 2014
67. Noone A-M, Lund JL, Mariotto A, et al: Comparison of SEER treatment data with Medicare claims. Med Care 54:e55-64, 2016
68. Seo GH, Cho YY, Chung JH, et al: Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: A nationwide, population-based study in Korea. Thyroid 25:927-934, 2015
69. Lang BH-H, Wong IOL, Wong KP, et al: Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 151:844-850, 2012
70. Silva-Vieira M, Carlinho Vaz S, Esteves S, et al: Second primary cancer in patients with differentiated thyroid cancer: Does radiiodine play a role? Thyroid off. J Am Thyroid Assoc 27:1068-1076, 2017
71. Kitahara CM, Berrington de Gonzalez A, Bouville A, et al: Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med 179:1034-1042, 2019
72. Hirsch D, Shohat T, Gorstein A, et al: Incidence of nonthyroidal primary malignancy and the association with (131)I treatment in patients with differentiated thyroid cancer. Thyroid 26:1110-1116, 2016
73. Lauby-Secretan B, Scoccianti C, Loomis D, et al: Body fatness and cancer—Viewpoint of the IARC Working Group. N Engl J Med 375:794-798, 2016
74. Brown AP, Chen J, Hitchcock YJ, et al: The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515, 2008
75. Wallner LP, Banerjee M, Reyes-Gastelum D, et al: Multi-level factors associated with more intensive use of radioactive iodine for low-risk thyroid cancer. J Clin Endocrinol Metab 106:e2402-e2412, 2021
76. Bresner L, Banach R, Rodin G, et al: Cancer-related worry in Canadian thyroid cancer survivors. J Clin Endocrinol Metab 100:977-985, 2015
77. Grant EJ, Brenner A, Sugiyama H, et al: Solid cancer incidence among the life span study of atomic bomb survivors: 1958-2009. Radiat Res 187:513-537, 2017
78. Gold EB, Bromberger J, Crawford S, et al: Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 153:865-874, 2001
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/fwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.